Skip to main content
Figure 1 | BMC Medicine

Figure 1

From: Commentary on the role of treatment-related HIV compensatory mutations on increasing virulence: new discoveries twenty years since the clinical testing of protease inhibitors to block HIV-1 replication

Figure 1

Schematic representation of the HIV-1 protease wireframe crystal structure and highlighting the secondary/compensatory selected under protease inhibitor treatment. (A) The wireframe cartoon of the protease X-ray crystal structure (PDB ID:3HVP ) is present to highlight the position of the secondary mutations (black dots) that compensate for fitness losses derived from primary drug resistance to protease inhibitors (red dots). (B) A schematic representation of the genetic diversity in the HIV-1 protease derived from the curated HIV-1 protease alignment from Los Alamos National Laboratories HIV sequence database. Alignments of protease and any amino acid found at >1% frequency is presented in this WebLogo (http://weblogo.berkeley.edu).

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us